Literature DB >> 1705174

Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression.

M Maxwell1, S P Naber, H J Wolfe, E T Hedley-Whyte, T Galanopoulos, J Neville-Golden, H N Antoniades.   

Abstract

Astrocytomas are highly malignant brain tumors and are among the most neovascularized solid tumors. We have investigated the expression of the angiogenic growth factors acidic fibroblast growth factor and transforming growth factor-alpha, together with its receptor epidermal growth factor receptor, in 30 primary astrocytomas. Both acidic fibroblast growth factor and transforming growth factor-alpha, together with epidermal growth factor receptor, are found to be greatly overexpressed in these tumors when compared with normal brain. This overexpression of angiogenic growth factors may underlie the intense neovascularization characteristic of astrocytomas.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1705174

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

Review 2.  Angiogenic growth factors in neural embryogenesis and neoplasia.

Authors:  D Zagzag
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

3.  Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences.

Authors:  Daniel Ruiz-Sánchez; Irene Iglesias Peinado; Miguel Alaguero-Calero; Alejandro José Sastre-Heres; Benito García Diez; Jaime Peña-Díaz
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

4.  Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.

Authors:  Daniel Ruiz-Sánchez; Miguel Alaguero Calero; Alejandro José Sastre-Heres; María Teresa Iglesias García; Miguel Angel Calleja Hernandez; Fernando Martínez Martinez; Jaime Peña-Díaz
Journal:  Oncol Lett       Date:  2012-08-14       Impact factor: 2.967

5.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

Authors:  F Yamaguchi; H Saya; J M Bruner; R S Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

6.  Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. A light microscopic and immunohistochemical study of formalin-fixed, routinely processed material.

Authors:  P Wesseling; J J Vandersteenhoven; B T Downey; D J Ruiter; P C Burger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

Authors:  C K Goldman; J Kim; W L Wong; V King; T Brock; G Y Gillespie
Journal:  Mol Biol Cell       Date:  1993-01       Impact factor: 4.138

8.  Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.

Authors:  Yazmin Odia; Joanna H Shih; Teri N Kreisl; Howard A Fine
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

9.  Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; W A Franklin; H G Morse; E B Spector; K O Lillehei
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

10.  Endothelial cell implantation and survival within experimental gliomas.

Authors:  B Lal; R R Indurti; P O Couraud; G W Goldstein; J Laterra
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.